...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Antimicrobial agents and chemotherapy. >Role of Pfmdr1 in In Vitro Plasmodium falciparum Susceptibility to Chloroquine, Quinine, Monodesethylamodiaquine, Mefloquine, Lumefantrine, and Dihydroartemisinin
【24h】

Role of Pfmdr1 in In Vitro Plasmodium falciparum Susceptibility to Chloroquine, Quinine, Monodesethylamodiaquine, Mefloquine, Lumefantrine, and Dihydroartemisinin

机译：Pfmdr1在体外恶性疟原虫对氯喹，奎宁，单去甲二酰胺，甲氟喹，鲁美替林和双氢青蒿素的敏感性中的作用

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The involvement of Pfmdr1 (Plasmodium falciparum multidrug resistance 1) polymorphisms in antimalarial drug resistance is still debated. Here, we evaluate the association between polymorphisms in Pfmdr1 (N86Y, Y184F, S1034C, N1042D, and D1246Y) and Pfcrt (K76T) and in vitro responses to chloroquine (CQ), mefloquine (MQ), lumefantrine (LMF), quinine (QN), monodesethylamodiaquine (MDAQ), and dihydroartemisinin (DHA) in 174 Plasmodium falciparum isolates from Dakar, Senegal. The Pfmdr1 86Y mutation was identified in 14.9% of the samples, and the 184F mutation was identified in 71.8% of the isolates. No 1034C, 1042N, or 1246Y mutations were detected. The Pfmdr1 86Y mutation was significantly associated with increased susceptibility to MDAQ (P=0.0023), LMF (P=0.0001), DHA (P=0.0387), and MQ(P=0.00002). The N86Y mutation was not associated with CQ (P=0.214) or QN (P=0.287) responses. The Pfmdr1 184F mutation was not associated with various susceptibility responses to the 6 antimalarial drugs (P=0.168 for CQ, 0.778 for MDAQ, 0.324 for LMF, 0.961 for DHA, 0.084 for QN, and 0.298 for MQ). The Pfmdr1 86Y-Y184 haplotype was significantly associated with increased susceptibility to MDAQ (P= 0.0136), LMF (P=0.0019), and MQ (P=0.0001). The additional Pfmdr1 86Y mutation increased significantly the in vitro susceptibility to MDAQ (P<0.0001), LMF (P<0.0001),MQ(P<0.0001), and QN (P=0.0026) in wild-type Pfcrt K76 parasites. The additional Pfmdr1 86Y mutation significantly increased the in vitro susceptibility to CQ (P=0.0179) in Pfcrt 76T CQ-resistant parasites.
机译：Pfmdr1（恶性疟原虫多药耐药性1）多态性与抗疟药耐药性的关系仍存在争议。在这里，我们评估了Pfmdr1（N86Y，Y184F，S1034C，N1042D和D1246Y）和Pfcrt（K76T）多态性与对氯喹（CQ），甲氟喹（MQ），lumantantrine（LMF），奎宁（QN）的体外反应之间的关联），174种来自塞内加尔达喀尔的恶性疟原虫分离株中的单去乙基氨二喹（MDAQ）和双氢青蒿素（DHA）。在14.9％的样品中鉴定出Pfmdr1 86Y突变，在71.8％的分离株中鉴定出184F突变。未检测到1034C，1042N或1246Y突变。 Pfmdr1 86Y突变与对MDAQ（P = 0.0023），LMF（P = 0.0001），DHA（P = 0.0387）和MQ（P = 0.00002）的敏感性增加显着相关。 N86Y突变与CQ（P = 0.214）或QN（P = 0.287）反应无关。 Pfmdr1 184F突变与对6种抗疟药的各种敏感性反应无关（CQ P = 0.168，MDAQ P = 0.78，LMF 0.324，DHA 0.961，QN 0.084，MQ 0.298）。 Pfmdr1 86Y-Y184单倍型与对MDAQ（P = 0.0136），LMF（P = 0.0019）和MQ（P = 0.0001）的敏感性增加显着相关。额外的Pfmdr1 86Y突变显着提高了野生型Pfcrt K76寄生虫对MDAQ（P <0.0001），LMF（P <0.0001），MQ（P <0.0001）和QN的体外敏感性。附加的Pfmdr1 86Y突变显着增加了对Pfcrt 76T CQ耐药的寄生虫对CQ的体外敏感性（P = 0.0179）。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号